Pharvaris' Deucrictibant Shows Strong Efficacy in HAE Treatment Trials
Event summary
- Pharvaris presented data at AAAAI 2026 showing deucrictibant met all primary and secondary endpoints in the RAPIDe-3 trial for on-demand HAE treatment.
- Deucrictibant achieved symptom relief in 1.28 hours and complete resolution in 11.95 hours, compared to placebo.
- CHAPTER-1 data confirmed long-term safety and efficacy for prophylactic use, with attack rates reducing from 2.18 to 0.12 attacks/month.
- Pharvaris is preparing marketing authorization applications for deucrictibant immediate-release capsule and anticipates topline data from the CHAPTER-3 study in Q3 2026.
The big picture
Pharvaris' data supports deucrictibant as a potential standard of care for HAE, addressing unmet needs with oral administration and rapid efficacy. The company is positioning itself to challenge injectable treatments, leveraging strong clinical results to drive regulatory approvals and market adoption. The success of deucrictibant could reshape the bradykinin-mediated angioedema treatment landscape.
What we're watching
- Regulatory Pathway
- Whether Pharvaris can secure marketing authorization for deucrictibant immediate-release capsule in the first half of 2026.
- Clinical Success
- The pace at which deucrictibant extended-release tablet demonstrates efficacy in the ongoing CHAPTER-3 study.
- Market Positioning
- How deucrictibant's differentiated profile will compete against existing therapies for bradykinin-mediated angioedema.
Related topics